Ferring Pharmaceutical officially opened its new 12,000-square-foot gene therapy manufacturing facility located within its US headquarters in Parsippany, New Jersey.

The new facility produces Adstiladrin, the first and only FDA-approved gene therapy delivered directly to the bladder for high-risk, non-muscle-invasive bladder cancer (NMIBC). 

According to reports, the company has invested more than $1 billion in developing ADSTILADRIN over 10 years. This included nearly $500 million in manufacturing investments.

The ribbon cuting ceremony held Sean T. Goudy, Vice President, Technical Operations, Parsippany, Ferring, Shala Gagliardi, Constituent Services Representative for Congresswoman Mikie Sherrill,  Brent Ragans, U.S. President, Ferring Pharmaceuticals, State Senator Joe Pennacchio, Parsippany Mayor James Barberio, Jean Frédéric Paulsen, Chairman Ferring Pharmaceuticals, Armin Metzger, Executive Vice President, Chief Technical Operations Officer, Fran, Bladder Cancer Patient,  Stephanie Chisolm, Director of Education and Advocacy at Bladder Care Advocacy Network.